Moderna (MRNA) · Biotechnology
Moderna Q2 2026 earnings: summary, key numbers & outlook
Results filed 31 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Moderna is awaiting a U.S. decision on its seasonal flu vaccine mFLUSIVA, which would be its fifth product, after a unanimous advisory committee recommendation, while its norovirus vaccine missed an early-success bar.
Moderna's flu vaccine mFLUSIVA won a unanimous FDA advisory committee recommendation ahead of an August 5 decision date, and the flu-plus-COVID shot mCOMBRIAX gained European Commission authorization. mRESVIA was approved in Australia and Mexico and mNEXSPIKE in Japan and Taiwan. Europe added a joint procurement contract for up to 24 million mRESVIA doses on behalf of six countries, and a Brazil manufacturing collaboration supports COVID vaccine supply. The norovirus vaccine did not meet early-success criteria at its interim analysis.
Management is steering toward a broader, more diversified portfolio: flu approvals, international partnerships, and pivotal readouts in 2026 for intismeran in melanoma and for the propionic acidemia therapy. The tension is that growth depends on a few binary events, including the U.S. flu decision, FDA guidance on refiling the combination vaccine, and COVID vaccination rates that may keep falling, while the norovirus program now needs another cohort.
No call transcript for this quarter, so this summary also draws on: Mitrade (transcript sourced from The Motley Fool) ↗.
Key numbers
- Total revenue · GAAP
- $145 million
- Net loss · GAAP
- $(0.8) billion
- Loss per share · GAAP
- $(1.97)
- Loss from operations · GAAP
- -815.0M
- Cash, cash equivalents and investments
- $6.9 billion
compared to $142 million in the same period in 2025
an improvement of $43 million, or 5%, compared to the second quarter of 2025
compared to $(2.13) for the second quarter of 2025
compared to (907) in the second quarter of 2025
compared to $7.5 billion as of March 31, 2026
| Segment or metric | Value | Change |
|---|---|---|
| U.S. revenue | $87 million | |
| International revenue | $58 million | |
| Net product sales | $94.0M | compared to $114 in the second quarter of 2025 |
Where each number comes from
- Total revenue: “Total revenue for the second quarter of 2026 was $145 million, compared to $142 million in the same period in 2025.”
- Net loss: “Net loss was $(0.8) billion for the second quarter of 2026, an improvement of $43 million, or 5%, compared to the second quarter of 2025.”
- Loss per share: “Loss per share was $(1.97) for the second quarter of 2026, compared to loss per share of $(2.13) for the second quarter of 2025.”
- Loss from operations: “Loss from operations | (815) | (907) | (2,203) | (1,957) Interest income | 67 | 81 | 139 | 171”
- Cash, cash equivalents and investments: “Cash, cash equivalents and investments as of June 30, 2026, were $6.9 billion, compared to $7.5 billion as of March 31, 2026.”
- U.S. revenue: “Revenue was $87 million in the U.S. and $58 million in international markets.”
- International revenue: “Revenue was $87 million in the U.S. and $58 million in international markets.”
- Net product sales: “Net product sales | $94 | $114 | $446 | $200 Other revenue1 | 51 | 28 | 88 | 50 Total revenue | 145 | 142 | 534 | 250”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $145.0M | +2.1% | −62.7% |
| Operating income | -$815.0M | +10.1% | +41.3% |
| Net income | -$782.0M | +5.2% | +41.8% |
| Diluted EPS | -$1.97 | +7.5% | +42.1% |
| Free cash flow | -$563.0M | +38.9% | +18.6% |
| Operating margin | -562.1% | +76.6 pts | −205.3 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Revenue growth from 2025 | 2026 | up to 10% |
| Share of second half revenue in the third quarter | second half of 2026 | approximately 55% |
| Cost of sales | 2026 | approximately $1.7 billion |
| Research and development expenses | 2026 | approximately $2.9 billion |
| Selling, general and administrative expenses | 2026 | approximately $1.0 billion |
| Capital expenditures | 2026 | $0.2 to $0.3 billion |
| Year-end cash and investments | year-end 2026 | $4.7 to $5.2 billion |
Key takeaways
mFLUSIVA could become Moderna's fifth approved product
The seasonal flu vaccine received a unanimous VRBPAC recommendation ahead of an August 5 PDUFA date. Approval would extend Moderna beyond COVID and RSV in the U.S.
Norovirus vaccine missed early-success bar at interim
mRNA-1403 did not meet statistical criteria for early success in Phase 3. The trial remains blinded and Moderna is preparing to enroll an additional cohort, which delays any answer.
International partnerships and approvals widen the commercial base
Moderna signed a joint EU procurement contract for up to 24 million mRESVIA doses and a Brazil manufacturing collaboration for COVID vaccines. New approvals came in Australia, Mexico, Japan and Taiwan.
Combination flu and COVID vaccine advances outside the U.S.
mCOMBRIAX received European Commission authorization and mRNA-1083 filings are under review in Japan, Canada and Australia. In the U.S., Moderna is still awaiting FDA guidance on refiling.
Intismeran oncology program expands toward pivotal data
Nine Phase 2 and Phase 3 trials with Merck are underway, and five-year Phase 2b melanoma data showed a 49% lower risk of recurrence or death versus KEYTRUDA alone. Phase 3 adjuvant melanoma data are potentially due in 2026.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $966.0M * |
| Q1 2025 | $108.0M |
| Q2 2025 | $142.0M |
| Q3 2025 | $1.0B |
| Q4 2025 | $678.0M * |
| Q1 2026 | $389.0M |
| Q2 2026 | $145.0M |
| Q3 2026 | $1.3B |
Data
| Q1 2025 | -$2.52 |
| Q2 2025 | -$2.13 |
| Q3 2025 | -$0.51 |
| Q1 2026 | -$3.40 |
| Q2 2026 | -$1.97 |
| Q3 2026 | $0.38 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | -129.0% |
| Q1 2025 | -972.2% |
| Q2 2025 | -638.7% |
| Q3 2025 | -25.6% |
| Q4 2025 | -126.4% |
| Q1 2026 | -356.8% |
| Q2 2026 | -562.1% |
| Q3 2026 | 9.9% |
Data
| Q4 2024 | $303.0M |
| Q1 2025 | -$1.2B |
| Q2 2025 | -$922.0M |
| Q3 2025 | -$880.0M |
| Q4 2025 | $891.0M |
| Q1 2026 | -$692.0M |
| Q2 2026 | -$563.0M |
| Q3 2026 | -$1.6B |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What is the next major U.S. catalyst for Moderna's product portfolio?
The FDA decision on mFLUSIVA, its seasonal flu vaccine, with a PDUFA date of August 5, 2026. Approval would make it Moderna's fifth approved product.
What happened with Moderna's norovirus vaccine?
Phase 3 mRNA-1403 did not meet statistical criteria for early success at the interim analysis. The trial is ongoing and blinded while Moderna works toward enrolling an additional cohort.
Where is Moderna expanding its vaccine business outside the U.S.?
It signed a joint EU procurement contract for up to 24 million mRESVIA doses for six countries and a Brazil manufacturing collaboration for COVID vaccines. It also received approvals in Australia, Mexico, Japan and Taiwan.
What is the status of Moderna's flu plus COVID combination vaccine?
mCOMBRIAX is authorized in the EU, and mRNA-1083 filings are under review in Japan, Canada and Australia. Moderna is awaiting FDA guidance on refiling in the U.S.
What pivotal readouts is Moderna expecting in 2026?
Phase 3 adjuvant melanoma data for intismeran, developed with Merck, and registrational data for its propionic acidemia therapy mRNA-3927. Moderna deferred a pivotal trial decision on its methylmalonic acidemia candidate until the PA readout.
Documents
SEC filing